Allena Pharmaceuticals, Inc., a Newton, MA-based biopharmaceutical company focused on developing and commercializing innovative non-systemic oral protein therapeutics to treat metabolic and orphan diseases, completed a $53m Series C financing. The round was led by Partner Fund Management with participation from new investors Fidelity Management & Research Company and Wellington Management Company, and existing investors Frazier Healthcare, HBM BioCapital, and Pharmstandard International, S.A.
Allena Pharmaceuticals is developing and commercializing non-systemic oral protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrologic and urologic conditions.
Allena was founded in 2011 and has received $43 million in venture capital financing led by top-tier venture investors, including Bessemer Venture Partners, Frazier Healthcare, Third Rock Ventures, HBM Healthcare Investments and other investors.
Based in Newton, Mass., Allena was co-founded by Alexey Margolin, Ph.D., and Robert Gallotto, industry leaders with a proven track record of success in protein therapeutic design and development. Allena is leveraging its leadership team’s combined operational expertise in manufacturing, formulation and non-systemic protein delivery.